Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393777 | 0.91 | RAB9A (0.63) | RAB9AHPGDSMN1; SMN2GRM5MEN1 | |
| SCHEMBL8245318 | 0.86 | RAB9A (0.57) | RAB9AHPGDSMN1; SMN2GRM5MEN1 | |
| SCHEMBL10720485 | 0.82 | L3MBTL3 (0.59) | HPGDMEN1KMT2AL3MBTL1L3MBTL3 | |
| SCHEMBL4736618 | 0.82 | RAB9A (0.58) | RAB9AHPGDSMN1; SMN2GRM5EPHX2 | |
| SCHEMBL13202942 | 0.81 | RAB9A (0.57) | RAB9AHPGDSMN1; SMN2GRM5EPHX2 | |
| SCHEMBL1980071 | 0.81 | L3MBTL3 (0.68) | RAB9AHPGDSMN1; SMN2GRM5EPHX2 | |
| SCHEMBL4534421 | 0.81 | MAPT (0.67) | RAB9AHPGDSMN1; SMN2GRM5MEN1 | |
| SCHEMBL4734136 | 0.80 | EPHX2 (0.60) | RAB9AHPGDSMN1; SMN2GRM5MEN1 | |
| SCHEMBL3242724 | 0.79 | RAB9A (0.65) | RAB9AHPGDSMN1; SMN2GRM5L3MBTL1 | |
| SCHEMBL31392086 | 0.79 | RAB9A (0.65) | RAB9AHPGDSMN1; SMN2GRM5L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | RAB9A 1585/4885HPGD 3387/4885SMN1; SMN2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.